Alkem Laboratories Ltd - Company Profile
Powered by 
All the data and insights you need on Alkem Laboratories Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Alkem Laboratories Ltd Strategy Report
- Understand Alkem Laboratories Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Alkem Laboratories Ltd (Alkem) develops, manufactures and markets generic and specialty pharmaceutical products. The company’s product portfolio includes active pharmaceutical ingredients, generic products, branded products and nutraceuticals. Alkem provides drugs for acute and chronic diseases such as central nervous system disorders, gastro-intestinal infections, metabolic disorders and diabetes, cancer, skin and hair diseases, urologic diseases, cardiovascular diseases, immune disorders and pain relief. It also offers vitamins, minerals and nutrition products. The company distributes its products directly through its subsidiaries or through a wide network of distributors over more than 40 countries. It also exports products to Germany, Australia, South-East Asia, the US, the UK, Russia-CIS, and Africa. Alkem is headquartered in Mumbai, Maharashtra, India.
Headquarters
India
Address
Almac House, Senapati Bapat Marg, Mumbai, Maharashtra, 400013
Website
www.alkemlabs.com
Telephone
91 22 39829999
No of Employees
16,871
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ALKEM (NSE)
Revenue (2022)
$1.5B
9.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-40.2%
(2022 vs 2021)
Market Cap*
$6.8B
Net Profit Margin (2022)
XYZ
-45.2%
(2022 vs 2021)
* As of and is in US$
Alkem Laboratories Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Therapeutic Areas: | Clavam |
| Vitamin and Nutrition | Pan |
| Cancer | Pan-D |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | New Products/Services | In May, the company launched Cetuxa, for the treatment of head and neck cancer. |
| 2023 | New Products/Services | In March, Enzene Biosciences announced the commercial release of its biosimilar for Adalimumab. |
| 2023 | New Products/Services | In January, the company launched novel antibiotic for Multiple drug resistance (MDR) infections under the brand name Zidavi. |
Competitor Comparison
| Key Parameters | Alkem Laboratories Ltd | Sun Pharmaceutical Industries Ltd | Aurobindo Pharma Ltd | Dr. Reddy's Laboratories Ltd | Cipla Ltd |
|---|---|---|---|---|---|
| Headquarters | India | India | India | India | India |
| City | Mumbai | Mumbai | Hyderabad | Hyderabad | Mumbai |
| State/Province | Maharashtra | Maharashtra | Telangana | Telangana | Maharashtra |
| No. of Employees | 16,871 | 41,000 | 15,690 | 24,832 | 26,615 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Basudeo N. Singh | Chairman | Executive Board | - | - |
| Sandeep Singh | Managing Director; Director | Executive Board | 2013 | - |
| Nitin Agrawal | Chief Financial Officer | Senior Management | 2024 | - |
| Mritunjay Kumar Singh | Director | Executive Board | 2008 | - |
| Madhurima Singh | Director | Executive Board | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer